Ren H, Wang C F
State Key Lab of Molecular Oncology, Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2020 Nov 23;42(11):903-906. doi: 10.3760/cma.j.cn112152-20190313-00152.
Pancreatic cancer, with the characteristics of insidious onset, easy metastasis, chemotherapy resistance and poor prognosis, is a common malignant tumor of the digestive system. Early diagnosis and treatment of pancreatic cancer is one of the major problems in modern medicine, and there is an urgent need to find new diagnostic, prognostic biomarkers and therapeutic targets. MicroRNA (miRNA) is a small non-coding RNA which can regulate the expression of various genes. miRNAs have wide abnormal expressions in pancreatic cancer, and are closely related to the occurrence and development of pancreatic cancer. Thereby, miRNAs have the potential to become new diagnostic, prognostic and predictive biomarkers and therapeutic targets of pancreatic cancer. Many studies have initially shown that miRNAs have the application value in the diagnosis, treatment and prognosis evaluation of pancreatic cancer, but there are still some difficulties in the practical application and promotion. The mechanisms of miRNAs in pancreatic cancer remain to be further studied.
胰腺癌是消化系统常见的恶性肿瘤，具有起病隐匿、易转移、化疗耐药及预后差等特点。胰腺癌的早期诊断与治疗是现代医学的主要难题之一，迫切需要寻找新的诊断、预后生物标志物及治疗靶点。微小RNA（miRNA）是一种可调控多种基因表达的小型非编码RNA。miRNA在胰腺癌中存在广泛的异常表达，且与胰腺癌的发生发展密切相关。因此，miRNA有潜力成为胰腺癌新的诊断、预后及预测生物标志物和治疗靶点。许多研究初步表明，miRNA在胰腺癌的诊断、治疗及预后评估中具有应用价值，但在实际应用和推广中仍存在一些困难。miRNA在胰腺癌中的作用机制仍有待进一步研究。
